144 related articles for article (PubMed ID: 18839018)
1. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification.
Wang SA; Tang G; Fadare O; Hao S; Raza A; Woda BA; Hasserjian RP
Mod Pathol; 2008 Nov; 21(11):1394-402. PubMed ID: 18839018
[TBL] [Abstract][Full Text] [Related]
2. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Ardanaz MT; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
Mod Pathol; 2016 Dec; 29(12):1541-1551. PubMed ID: 27562492
[TBL] [Abstract][Full Text] [Related]
3. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
[TBL] [Abstract][Full Text] [Related]
4. Significance of fetal hemoglobin-containing erythroblasts (F blasts) and the F blast/F cell ratio in myelodysplastic syndromes.
Choi JW; Kim Y; Fujino M; Ito M
Leukemia; 2002 Aug; 16(8):1478-83. PubMed ID: 12145688
[TBL] [Abstract][Full Text] [Related]
5. Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease.
Kasyan A; Medeiros LJ; Zuo Z; Santos FP; Ravandi-Kashani F; Miranda R; Vadhan-Raj S; Koeppen H; Bueso-Ramos CE
Mod Pathol; 2010 Aug; 23(8):1113-26. PubMed ID: 20473273
[TBL] [Abstract][Full Text] [Related]
6. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
7. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.
Senent L; Arenillas L; Luño E; Ruiz JC; Sanz G; Florensa L
Haematologica; 2013 Apr; 98(4):568-75. PubMed ID: 23065505
[TBL] [Abstract][Full Text] [Related]
9. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.
Alkharabsheh O; Patnaik MM; Gangat N; Begna KH; Alkhateeb HB; Shah MV; Hogan WJ; He R; Greipp P; Nguyen PL; Litzow MR; Al-Kali A
Ann Hematol; 2020 Mar; 99(3):513-518. PubMed ID: 31974678
[TBL] [Abstract][Full Text] [Related]
10. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
Mangi MH; Mufti GJ
Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes.
Molteni A; Riva M; Cesana C; Speziale V; Nichelatti M; Scarpati B; Greco R; Ravano E; Cairoli R; Rossini S; Morra E
Eur J Haematol; 2015 Jun; 94(6):519-25. PubMed ID: 25307971
[TBL] [Abstract][Full Text] [Related]
12. Counting bone marrow blasts as a percentage of nonerythroid cells improves the prognostic evaluation of MDS with erythroid predominance.
Yu Y; Zhang T; Wang Q; Wu D; Pan J; Liang J; Chen S; Sun A
Am J Hematol; 2017 Apr; 92(4):E55-E57. PubMed ID: 28133867
[No Abstract] [Full Text] [Related]
13. Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).
Bennett JM; Tuechler H; Aul C; Strupp C; Germing U
Leuk Res; 2016 Aug; 47():63-9. PubMed ID: 27258735
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases.
Kowal-Vern A; Mazzella FM; Cotelingam JD; Shrit MA; Rector JT; Schumacher HR
Am J Hematol; 2000 Sep; 65(1):5-13. PubMed ID: 10936857
[TBL] [Abstract][Full Text] [Related]
15. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Uchida T; Hagihara M; Hua J; Inoue M
Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
[TBL] [Abstract][Full Text] [Related]
16. PAS positivity of erythroid precursor cells is associated with a poor prognosis in newly diagnosed myelodysplastic syndrome patients.
Masuda K; Shiga S; Kawabata H; Takaori-Kondo A; Ichiyama S; Kamikubo Y
Int J Hematol; 2018 Jul; 108(1):30-38. PubMed ID: 29600427
[TBL] [Abstract][Full Text] [Related]
17. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
[TBL] [Abstract][Full Text] [Related]
18. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
19. Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.
Wang SA; Patel KP; Pozdnyakova O; Peng J; Zuo Z; Dal Cin P; Steensma DP; Hasserjian RP
Mod Pathol; 2016 Oct; 29(10):1221-31. PubMed ID: 27443511
[TBL] [Abstract][Full Text] [Related]
20. Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification.
Liu W; Hasserjian RP; Hu Y; Zhang L; Miranda RN; Medeiros LJ; Wang SA
Mod Pathol; 2011 Mar; 24(3):375-83. PubMed ID: 21102413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
